Search Results - "Lunin, Scott D."

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma by Flinn, Ian W, Miller, Carole B, Ardeshna, Kirit M, Tetreault, Scott, Assouline, Sarit E, Mayer, Jiri, Merli, Michele, Lunin, Scott D, Pettitt, Andrew R, Nagy, Zoltan, Tournilhac, Olivier, Abou-Nassar, Karem-Etienne, Crump, Michael, Jacobsen, Eric D, de Vos, Sven, Kelly, Virginia M, Shi, Weiliang, Steelman, Lori, Le, NgocDiep, Weaver, David T, Lustgarten, Stephanie, Wagner-Johnston, Nina D, Zinzani, Pier Luigi

“…Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies…”
Get full text

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia by Roboz, Gail J., Kantarjian, Hagop M., Yee, Karen W. L., Kropf, Patricia L., O'Connell, Casey L., Griffiths, Elizabeth A., Stock, Wendy, Daver, Naval G., Jabbour, Elias, Ritchie, Ellen K., Walsh, Katherine J., Rizzieri, David, Lunin, Scott D., Curio, Tania, Chung, Woonbok, Hao, Yong, Lowder, James N., Azab, Mohammad, Issa, Jean‐Pierre J.

“…BACKGROUND Outcomes for patients with relapsed or refractory acute myeloid leukemia (AML) are poor. Guadecitabine, a next‐generation hypomethylating agent,…”
Get full text

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial by Sharman, Jeff P, Brander, Danielle M, Mato, Anthony R, Ghosh, Nilanjan, Schuster, Stephen J, Kambhampati, Suman, Burke, John M, Lansigan, Frederick, Schreeder, Marshall T, Lunin, Scott D, Zweibach, Alexander, Shtivelband, Mikhail, Travis, Patrick M, Chandler, Jason C, Kolibaba, Kathryn S, Sportelli, Peter, Miskin, Hari P, Weiss, Michael S, Flinn, Ian W

“…Patients with chronic lymphocytic leukaemia and high-risk features have poorer outcomes on ibrutinib than those without high-risk features. The aim of this…”
Get full text

Suppurative Parotitis by Lunin, Scott D, Moll, Stephan

“…Figure 1. A 60-year-old woman with a history of metastatic neuroendocrine tumor presented with rapidly progressive swelling of the left side of the face. She…”
Get full text

Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study by Sharman, Jeff P., Brander, Danielle M., Mato, Anthony R., Ghosh, Nilanjan, Schuster, Stephen J., Kambhampati, Suman, Burke, John M., Lansigan, Frederick, Schreeder, Marshall T., Lunin, Scott D, Zweibach, Alexander, Shtivelband, Mikhail, Travis, Patrick M., Chandler, Jason Claud, Kolibaba, Kathryn S., Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Flinn, Ian

“…Abstract only 8022 Background: The BTK inhibitor ibrutinib (IB) has advanced the treatment for patients (pts) with CLL, however, among pts with high-risk CLL,…”
Get full text

Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration by Savona, Michael R., Kantarjian, Hagop M., Roboz, Gail J., O'Connell, Casey L., Walsh, Katherine J., Tibes, Raoul, Yee, Karen W.L., Stock, Wendy, Griffiths, Elizabeth A., Jabbour, Elias, Lunin, Scott D., Rosenblat, Todd L., Podoltsev, Nikolai A., Issa, Jean-Pierre, Su, Xiang Yao, Azab, Mohammad, Garcia-Manero, Guillermo

“…Background: Guadecitabine is a next generation subcutaneous (SC) hypomethylating agent (HMA) resistant to degradation by cytidine deaminase which results in…”
Get full text

Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients by Griffiths, Elizabeth A., Kantarjian, Hagop M., O'Connell, Casey L., Yee, Karen W.L., Stock, Wendy, Daver, Naval G., Jabbour, Elias, Ritchie, Ellen K., Issa, Jean-Pierre, Walsh, Katherine J., Rizzieri, David A., Lunin, Scott D., Su, Xiang Yao, Azab, Mohammad, Roboz, Gail J.

“…Background: Guadecitabine is a next generation subcutaneous (SC) hypomethylating agent (HMA) resistant to degradation by cytidine deaminase which results in…”
Get full text

Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) by Garcia-Manero, Guillermo, Ritchie, Ellen K., Walsh, Katherine J., Savona, Michael R., Kantarjian, Hagop M., Kropf, Patricia L., O'Connell, Casey L., Tibes, Raoul, Daver, Naval G., Jabbour, Elias J., Lunin, Scott D., Rosenblat, Todd L., Yee, Karen W.L., Stock, Wendy, Griffiths, Elizabeth A., Mace, Joseph, Podoltsev, Nikolai A., Berdeja, Jesus G., Issa, Jean-Pierre, Naim, Sue, Hao, Yong, Azab, Mohammad, Roboz, Gail J.

“…Background: Guadecitabine SC (SGI-110) is a dinucleotide next generation HMA resistant to degradation by cytidine deaminase resulting in extended in vivo…”
Get full text

Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study) by Weaver, David T., Sprott, Kam, Pachter, Jonathan, Le, Ngocdiep T., Davids, Matthew Steven, Montillo, Marco, Illés, Árpád, Etienne, Gabriel, Delgado, Julio, Kuss, Bryone J., Tam, Constantine, Offner, Fritz, Lunin, Scott D., Bosch, Francesc, Hillmen, Peter, Lamanna, Nicole, Stilgenbauer, Stephan, Zinzani, Pier Luigi, Flinn, Ian, Brown, Jennifer R.

“…Abstract only…”
Get full text

Results from the Phase 3 DUOTM Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma by Flinn, Ian W., Hillmen, Peter, Montillo, Marco, Nagy, Zsolt, Illés, Árpád, Etienne, Gabriel, Delgado, Julio, Kuss, Bryone Jean, Tam, Constantine S., Gasztonyi, Zoltán, Offner, Fritz, Lunin, Scott D, Bosch, Francesco, Davids, Matthew S., Lamanna, Nicole, Jaeger, Ulrich, Ghia, Paolo, Cymbalista, Florence, Portell, Craig A., Skarbnik, Alan P, Cashen, Amanda, Kelly, Virginia, Turnbull, Barry, Stilgenbauer, Stephan

“…Background: Despite the recent development of novel targeted therapies to treat chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), the…”
Get full text

Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study by Sharman, Jeff Porter, Brander, Danielle M., Mato, Anthony R., Kambhampati, Suman, Burke, John M., Lansigan, Frederick, Schreeder, Marshall T., Lunin, Scott D., Ghosh, Nilanjan, Zweibach, Alexander, Shtivelband, Mikhail, Travis, Patrick M., Chandler, Jason Claud, Kolibaba, Kathryn S., Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Flinn, Ian

“…Abstract only 7504 Background: Patients (pts) with high-risk chronic lymphocytic leukemia (CLL) defined by interruptions in TP53 (either by mutation or…”
Get full text

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma by Flinn, Ian W., Miller, Carole B., Ardeshna, Kirit M, Tetreault, Scott, Assouline, Sarit E., Zinzani, Pier Luigi, Mayer, Jiri, Merli, Michele, Lunin, Scott D, Pettitt, Andrew R., Nagy, Zsolt, Tournilhac, Oliver, Abou-Nassar, Karim Etienne, Crump, Michael, Jacobsen, Eric D., de Vos, Sven, Santabarbara, Pedro, Shi, Weiliang, Steelman, Lori, Wagner-Johnston, Nina D.

“…DYNAMO: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma Introduction:…”
Get full text

First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) by Griffiths, Elizabeth A., Kantarjian, Hagop M., Roboz, Gail J., Kropf, Patricia Lamont, O'Connell, Casey Lee, Yee, Karen W. L., Garcia-Manero, Guillermo, Jabbour, Elias, Feldman, Eric Jay, Walsh, Katherine Jean, Rizzieri, David, Stock, Wendy, Lunin, Scott D., Naim, Sue, Choy, Gavin S., Taverna, Pietro, Hao, Yong, Azab, Mohammad, Chung, Woonbok, Issa, Jean-Pierre J.

“…Abstract only…”
Get full text

DYNAMO: A phase 2 trial of the PI3K-δ,γ inhibitor IPI-145 in patients with refractory indolent non-Hodgkin lymphoma by Wagner-Johnston, Nina, Strickland, Donald K, Wright, David Donald, Tetreault, Scott A., Lunin, Scott D., Essell, James H., Webb, Charles D., Langdon, Robert M., Farber, Charles M., Nimeh, Nadim F., Marris, Mike, Coleman, Teresa A., Kelly, Patrick Francis, Steelman, Lori, Dewar, Karen, Pimental, Patricia, Flinn, Ian

“…Abstract only…”
Get full text

Images in clinical medicine. Suppurative parotitis by Lunin, S D, Moll, S

“…A 60-year-old woman with a history of metastatic neuroendocrine tumor presented with rapidly progressive swelling of the left side of the face. She was…”
Get full text

Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses by Abrams, S I, Stanziale, S F, Lunin, S D, Zaremba, S, Schlom, J

“…Mutant ras p21 proteins contain sequences which distinguish them from normal endogenous ras and, thus, may represent unique epitopes for T cell recognition of…”
Get more information

Release properties of isolated neuromuscular boutons of the garter snake by Wilkinson, R S, Son, Y J, Lunin, S D

“…1. Motor nerve terminals innervating fibres in the transversus abdominis muscle of the garter snake comprise discrete boutons. Using a combination of enzymatic…”
Get full text